Tag: Paragon BioTeck News
Alejandro Arboleda Named 2018 Koch Kellan Scholar by Paragon BioTeck, Inc.
PORTLAND, Ore., April 13, 2018 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., an ophthalmic pharmaceutical and medical device company, announced today that Alejandro Arboleda has been named its 2018 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to elevating the standard of eye care through social responsibility and a clinical, teaching or research career in ophthalmology.
Paragon BioTeck Invites Emerging Visionaries to Apply for 2018 Koch Kellan Ophthalmology Scholarship
PORTLAND, Ore., Oct. 2, 2017 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, today announced the call for the next Koch Kellan Scholar. The annual Koch Kellan Scholarship honors one outstanding graduate medical student committed to elevating the standard of eye care through social responsibility and a clinical, teaching, or research career in ophthalmology. A Paragon Gives initiative, the scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs.
Outstanding Graduate Medical Student Ms. Xinxin Zhang Named 2017 Koch Kellan Scholar
PORTLAND, Ore., April 12, 2017 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., an ophthalmic pharmaceutical and device company, announced today that Xinxin Zhang has been named its 2017 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology.
USPTO Ruling Affirms Patent Claim for Paragon BioTeck R-Phenylephrine Hydrochloride
PORTLAND, Ore., Nov. 21, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc. (Paragon), announces a monumental ruling handed down by the United States Patent and Trademark Office affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.
Paragon BioTeck Inc. announces 2017 Koch Kellan Scholarship, awarded annually to an outstanding graduate medical student
PORTLAND, Ore., Sept. 1, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today a call for applications for the 2017 Koch Kellan Scholarship, awarded annually to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology. A Paragon Gives initiative, the Koch Kellan Scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs and improve the quality of lives around the world.
